1. Associazione Italiana di Oncologia Medica. Linee Guida Gestione della tossicità ematopoietica in oncologia Milan; 2017.
http://media.aiom.it/userfiles/files/doc/LG/2017_LGAIOM_Toss_ematopoietica.pdf
. Accessed 25 Jan 2018.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia WorkGroup. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4).
https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf
. Accessed 25 Jan 2018.
3. Sistema Nazionale Linee Guida -Istituto Superiore di Sanità, Società Italiana di Nefrologia, Ministero della Salute. Linea Guida “Identificazione, prevenzione e gestione della Malattia Renale Cronica nell’adulto”. 2015.
https://www.fadoi.org/wp-content/uploads/2017/05/lineeguida-Malattia-renale-cronica-adulto.pdf
. Accessed 25 Jan 2018.
4. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13(Suppl 3):33–6.
5. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology, American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996–5010.